RNAC

Cartesian Therapeutics Stock Analysis

AI Rating

Low
  • Quality0/10
  • Growth↑ 7/10
  • Value↓ 0/10
Cartesian Therapeutics sales and earnings growth
RNAC Growth
Good
  • Revenue Y/Y↓ -94.81%
  • EPS Y/Y↓ -436.36%
  • FCF Y/Y↓ -93.05%
Cartesian Therapeutics gross and profit margin trends
RNAC Profitability
Low
  • Gross margin ↑ 100.00%
  • EPS margin↓ -8698.70%
  • ROIC 5Y↓ -132.31%
Cartesian Therapeutics net debt vs free cash flow
RNAC Risk
Great
  • Debt / Equity↓ 0.0
  • Debt / FCF↓ 0.0
  • Interest coverage↓ NA

Cartesian Therapeutics stock volatility is higher than the overall market. We give it a Great risk rating.

↗ More Biotechnology stocks